Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01076322
Recruitment Status : Completed
First Posted : February 26, 2010
Last Update Posted : August 12, 2010
Sponsor:
Information provided by:
Taiwan Otsuka Pharm. Co., Ltd

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Ventolin® MDI in stable asthma patients.

Condition or disease Intervention/treatment Phase
Asthma Drug: Meptin® Swinghaler Drug: Ventolin® MDI Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment-A sequence
Meptin® Swinghaler / Ventolin® MDI
 Drug: Meptin® Swinghaler

Meptin® Swinghaler®

  • Ingredient: Procaterol HCL
  • Dosage form: 10g/puff
  • Dose(s): 10g
  • Dosing schedule: 20g (total 20g)
Other Names:
  • Meptin® Swinghaler®
  • Procaterol HCL
  • Ventolin® MDI
  • Salbutamol sulfate

Drug: Ventolin® MDI

Ventolin® MDI

  • Ingredient: Salbutamol sulfate
  • Dosage form: 100g/puff
  • Dose(s): 100g
  • Dosing schedule: 200g (total 200g)
Experimental: Treatment-B sequence
Ventolin® MDI / Meptin® Swinghaler
 Drug: Meptin® Swinghaler

Meptin® Swinghaler®

  • Ingredient: Procaterol HCL
  • Dosage form: 10g/puff
  • Dose(s): 10g
  • Dosing schedule: 20g (total 20g)
Other Names:
  • Meptin® Swinghaler®
  • Procaterol HCL
  • Ventolin® MDI
  • Salbutamol sulfate

Drug: Ventolin® MDI

Ventolin® MDI

  • Ingredient: Salbutamol sulfate
  • Dosage form: 100g/puff
  • Dose(s): 100g
  • Dosing schedule: 200g (total 200g)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The change in Forced Expiratory Volume in 1 second (FEV1) value. [ Time Frame: 2 days ]

Secondary Outcome Measures :
  1. The change in sGaw [ Time Frame: 2 days ]
  2. The changes in IOS parameters (R, X and RF) [ Time Frame: 2 days ]
  3. The change in Peak Expiratory Flow Rate (PEFR) [ Time Frame: 2 days ]
  4. The change in Forced Vital Capacity (FVC) [ Time Frame: 2 days ]
  5. The change in Oxygen Saturation (SpO2) [ Time Frame: 2 days ]
  6. The change in Borg scale [ Time Frame: 2 days ]
  7. Device acceptance [ Time Frame: 2 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or females outpatients aged ≥ 16 years old with stable mild to moderate persistent asthma; Stability was assessed the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days;

  2. Pulmonary function test:

    • Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ;
    • Positive result of Broncho-provocation test (PC20 ≤ 32 mg/ml) before the study.
  3. Baseline forced expiratory volume in one second 60% ≤(FEV1)≤ 90% of predicted value on entry of the study;

Exclusion Criteria:

  1. Hypersensitivity to β2-agonist or lactose;
  2. Hospitalization due to asthma during the previous 3months;
  3. Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
  4. Oral or systemic corticosteroids in the previous 4weeks;
  5. Inadequately controlled hyperthyroidism;
  6. Severe hepatic or renal or cardiovascular disease as judged by the investigator;
  7. Patients receive an investigational drug within 30 days prior to admission to the study;
  8. Patients with significant alcohol, drug or medication abuse as judged by the investigator;
  9. Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01076322


Locations
Layout table for location information
Taiwan
Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taiwan Otsuka Pharm. Co., Ltd
Investigators
Layout table for investigator information
Principal Investigator: Ping-Hung Kuo, MD National Taiwan University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Edward C.Y. Peng, Taiwan Otsuka Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier: NCT01076322     History of Changes
Other Study ID Numbers: 002-TWB-0801
First Posted: February 26, 2010    Key Record Dates
Last Update Posted: August 12, 2010
Last Verified: February 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Albuterol
Procaterol
Bronchodilator Agents
Autonomic Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Sympathomimetics